Macrothrombocytopenia and progressive deafness is due to a mutation in MYH9.

Otol Neurotol

Laboratory of Molecular Otology, Epstein Laboratories, Department of Otolaryngology-Head & Neck Surgery, University of California San Francisco, CA 94143, USA.

Published: March 2003

Background: In 1992, a family with hereditary macrothrombocytopenia and progressive sensorineural hearing impairment without renal dysfunction was described. Recently, mutations in MYH9, a nonmuscle myosin heavy chain, have been found in several forms of hereditary macrothrombocytopenia.

Hypothesis: The hereditary macrothrombocytopenia and hearing loss in the previously reported family is due to a mutation in MYH9 gene.

Methods: Genomic DNA was extracted from the affected proband. Mutation screening of all MYH9 coding exons was carried out using denaturing high-performance liquid chromatography. Abnormal results were followed by direct sequencing of the exon and comparison of the sequence with the normal MYH9 sequence.

Results: The results of denaturing high-performance liquid chromatography suggested a potential sequence alteration in exon 30 of MYH9. Direct sequence analysis of this exon in the affected individual identified a G to A single base pair transition at nucleotide 4270 altering codon 1424. This mutations leads to an amino acid change from aspartate (D) to asparagine (N) in the highly conserved coiled-coil domain.

Conclusions: A single base pair transition in MYH9, resulting in an amino acid substitution D1424N, is responsible for macrothrombocytopenia and hearing loss in the kindred under study. The presence of hearing impairment and the absence of renal symptoms, as reported in other families with the same mutation MYH9, further highlights the role of genetic background in expression and modification of the affected phenotype.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00129492-200303000-00013DOI Listing

Publication Analysis

Top Keywords

mutation myh9
12
macrothrombocytopenia progressive
8
myh9
8
hereditary macrothrombocytopenia
8
hearing impairment
8
macrothrombocytopenia hearing
8
hearing loss
8
denaturing high-performance
8
high-performance liquid
8
liquid chromatography
8

Similar Publications

Background: Myosin heavy chain 9-related diseases (MYH9-RDs) are rare autosomal dominant platelet disorders characterized by macrothrombocytopenia and leukocyte inclusion bodies. They can manifest with nonhematological complications, including deafness, nephropathy, or cataracts. Due to its rarity and its similar clinical presentation with immune thrombocytopenia (ITP), MYH9-RD is often misdiagnosed as ITP, leading to inappropriate treatment and delayed management of complications.

View Article and Find Full Text PDF

May-Hegglin anomaly associated nephropathy: Case series.

SAGE Open Med Case Rep

November 2024

Division of Nephrology, Hypertension and Transplant Nephrology, University of California, Irvine, CA, USA.

May-Hegglin anomaly (MHA) is a rare autosomal dominant disease associated with a mutation in the MYH-9 gene. It is characterized by macrothrombocytopenia and neutrophils with abnormal cytoplasmic inclusions. Clinical features of this disease include hearing loss, early cataracts, and renal failure.

View Article and Find Full Text PDF

Non-muscle myosin (NMII) motor proteins have diverse developmental functions due to their roles in cell shape changes, cell migration, and cell adhesion. Zebrafish are an ideal vertebrate model system to study the NMII encoding myh genes and proteins due to high sequence homology, established gene editing tools, and rapid ex utero development. In humans, mutations in the NMII encoding MYH genes can lead to abnormal developmental processes and disease.

View Article and Find Full Text PDF

Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma.

Cell Death Dis

October 2024

Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, P.R. China.

Chemotherapy resistance has been a great challenge in pancreatic ductal adenocarcinoma(PDAC) treatments. Current first-line chemotherapy regimens for PDAC include gemcitabine-based regimens such as AG regimen (albumin paclitaxel and gemcitabine), fluorouracil-based regiments such as FOLFIRINOX regimen ((5-fluorouracil5-FU), oxaliplatin, Irinotecan) and platinum-based regimens for patients with BRCA mutations. large amounts of work have been done on exploring the mechanism underlying resistance of gemcitabine-based and platinum-based regimens, while little research has been achieved on the mechanism of FOLFIRINOX regimens resistance.

View Article and Find Full Text PDF

Unraveling MYH9-related disease: A case study on misdiagnosis with idiopathic thrombocytopenic purpura, confirmed through genetic.

Heliyon

September 2024

Department of Respiratory and Critical Care Medicine, Sichuan Provincial People's Hospital, No.32, West 2nd Section, 1st Ring Road, Qingyang District, Chengdu, 610072, Sichuan Province, China.

Article Synopsis
  • * The diagnosis was confirmed through advanced slide reading technology that identified specific features in the patient's blood samples, leading to genetic testing that revealed a mutation in the MYH9 gene.
  • * The report emphasizes the importance of recognizing hematologic signs and integrating genetic testing into standard diagnostic procedures to enhance patient care and avoid misdiagnoses like this one.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!